A CASE REPORT ON A RARE COMPLICATION OF HMG-COA REDUCTASE INHIBITORS.

2021 ◽  
pp. 46-47
Author(s):  
Sethu Babu ◽  
Billakuduru Srija ◽  
Mandhala Sai Krishna ◽  
Kalvakollu Keerthi
Keyword(s):  
Adverse Effect ◽  
Case Report ◽  
Rare Complication ◽  
Chief Complaint ◽  
Severe Mitral Regurgitation ◽  
Upper Limbs ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

Rhabdomyolysis is the rare adverse effect of statin therapy. It is a condition characterized by the damage and breakdown of skeletal muscle. A 66 years old male patient was admitted to the hospital with the chief complaint of pain and weakness in both lower and upper limbs for ve days and was diagnosed with statin-induced rhabdomyolysis. The signicance of statin-induced rhabdomyolysis in a patient with recent Hepatitis B related Decompensated Chronic Liver Disease with portal Hypertension, and Severe Mitral Regurgitation is highlighted here. Based on this case report, we recommend that clinicians should inform regular follow-up to the patients when prescribing statins.

C-MYC, HER2, and HER3 expression in localized prostate cancer (PC) treated with radical radiotherapy: Modulation by statins use and correlation with time to progression.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16045-e16045
Author(s):  
Davis Yuri Torrejon ◽  
Cristina Suarez ◽  
Xavier Maldonado ◽  
Alejandra Navarro ◽  
Rafael Morales ◽  
...  
Keyword(s):  
Risk Category ◽  
Radical Radiotherapy ◽  
Time To Progression ◽  
Treatment Groups ◽  
Reductase Inhibitors ◽  
Her3 Expression ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Semiquantitative Method

e16045 Background: There has been growing interest in the activity of statins (St) in PC patients receiving definitive radiation therapy. The oncogene Ras can be inhibited by HMG-CoA reductase inhibitors that in turn are also able to downregulate Myc. The aim of this study was to correlate St use and progression with the c-Myc, HER2 and HER3 expression in PC treated with radical radiotherapy (RT) with concurrent androgen deprivation. Methods: A total of 85 patients diagnosed with localised PC between 2000 and 2005 were selected for the study. Inmunohistochemical assay on core biopsy of each patient was performed using monoclonal antibodies for c-Myc, HER2 and HER3. The expression was evaluated using a semiquantitative method (Hscore scale: 0 to 300). Clinical and pathological variables were compared between St users and non-users and correlated with expression of c-Myc, HER2 and HER3. St users were defined as patients who had been taking St for at least 2 years before the diagnosis of PC and during follow up. Time to progression (TTP) was analyzed. Results: Mean age was 71 (56-82) years. Median follow-up was 75 months after RT. Twenty-five patients (29.4%) were using St. No statistical differences were found between treatment groups regarding median age, risk category, clinical T stage, Gleason score or median radiation dose. Median Hscore value of c-Myc was 40 (5-210) for St users vs. 72.5 (5-280) for non-users (p = 0.01). Only 8.6% of the cases showed HER2 expression and in those staining was mild intense and focal. Moderate expression of HER3 was observed in 36 cases (41.8%) and no correlation with St users nor with TTP was demonstrated (p=0.8). At the time of analysis, only 13 pts (15.3%) had biochemical relapse (1 low risk, 3 intermediate, and 9 high risk). St use (46.2%) was significantly associated with improved TTP (55 vs. 36.2 months, p = 0.022). Conclusions: Our work implicates a correlation of St use with a significant lower c-Myc expression and improvement in TTP in all groups, regardless the risk. No correlation was reported between HER2 or HER3, TTP and St use.

scholarly journals Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine

2021 ◽  
Vol 11 ◽  
Author(s):  
Takatoshi Anno ◽  
Tomoki Yamatsuji ◽  
Koichi Tomoda ◽  
Shuhei Nakanishi ◽  
Hideaki Kaneto
Keyword(s):  
Colon Cancer ◽  
Acute Pancreatitis ◽  
Case Report ◽  
Side Effects ◽  
Ldl Cholesterol ◽  
Sigmoid Colon Cancer ◽  
Long Period ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

Capecitabine has been used for the treatment of various types of tumors. The rare side effects induced by capecitabine have been reported as hypertriglyceridemia, acute pancreatitis associated with hypertriglyceridemia and hypertriglyceridemia complicated with hyperglycemia. The mechanisms of capecitabine-induced hypertriglyceridemia are unclear. In this report, we present a subject with sigmoid colon cancer and capecitabine-induced dyslipidemia. LDL-cholesterol level was markedly elevated throughout the long period of treatment with capecitabine. In addition, triglyceride level was high and not stable during the treatment period. Her dyslipidemia was ameliorated by the treatment with 5 mg of rosuvastatin, which is one of the HMG-CoA reductase inhibitors.

scholarly journals Statins May Increase Intracerebral Hemorrhage Volume

2010 ◽  
Vol 37 (6) ◽  
pp. 791-796 ◽  
Author(s):  
Geneviève Ricard ◽  
Marie-Pierre Garant ◽  
Nathalie Carrier ◽  
Nancy Leblanc ◽  
Jean-Martin Boulanger
Keyword(s):  
Intracerebral Hemorrhage ◽  
Primary Outcome ◽  
Ct Scans ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Hemorrhage Volume ◽  
Secondary Outcomes ◽  
Coa Reductase ◽  
Brain Hemorrhages

AbstractBackground:Some studies have suggested an association between hypocholesterolemia and intracerebral hemorrhage (ICH). In the SPARCL trial, statin use increased ICH risk. We tested the hypothesis that use of statins affects the volume of spontaneous ICH and contributes to the progression of ICH volume between baseline and follow-up CT scans.Methods:Consecutive cases of spontaneous ICH were reviewed. Secondary causes were excluded. We measured ICH volume on the baseline and follow-up CT scans using the AxBxC/2 method. Multivariate analysis and logistic regression modeling were used. The primary outcome was the ICH volume on the baseline CT scan. Secondary outcomes included volume variation between the baseline and the first follow up CT scans and death.Results:Of 303 subjects, 71 were taking a statin at the time of the ICH (23%). Statin users were significantly more likely to be younger, to have co-morbidities and take anticoagulant or anti-platelet medication. They also had a higher baseline ICH volume than non-statin users (median 31.2 [10,82.1] ml vs 16 [4,43.8] ml; p=0.006). Adjusting for possible confounders, statins remained associated with an increased ICH volume (p=0.007). There was a significant mean ICH volume progression between the first and second CT scans in statin users (+10.8 vs +0.9 ml; p=0.03; 95% CI: [-1,+22.6] [-2.5,+4.3]). No difference in mortality was seen between the two groups.Conclusion:Treatment with HMG-CoA reductase inhibitors may be a risk factor for increased ICH volume in spontaneous brain hemorrhages and could contribute to hemorrhage's volume progression.

scholarly journals The Role of HMG COA Reductase Inhibitors on the Progression of Coronary Artery Disease: Focus on Prediction Model

2019 ◽  
Vol 0 (0) ◽  
Author(s):  
Vladislava Stojic ◽  
Bojana Andjelkovic Cirkovic ◽  
Nebojsa Zdravkovic ◽  
Jelena Dimitrijevic ◽  
Vladan Kocic ◽  
...  
Keyword(s):  
Significant Interaction ◽  
Clinical Status ◽  
Initial Time ◽  
Current Therapy ◽  
Patient Specific ◽  
Reductase Inhibitors ◽  
Significant Difference ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

Abstract Currently, an integrated site-specific and patient-specific comprehensive predictive model of plaque progression in various CVD is not available. In this study, we considered medical records of 256 patients obtained within the EU H2020 SMARTool project which is carefully designed to collect the features from various domains relevant for disease which are used in everyday clinical practice. The database contains detailed information of patients with suspected CAD disease regarding the clinical status, risk factors, routine blood analyses, CAD morphology and progression and current therapy. Results showed that there was statistically significant difference of values of this parameter for the SMARTool patients with and without disease progression, measured at the follow-up, F(1,250)=33.39, p < 0.001, while the CAD Score in the follow-up is significantly different from the score measured at the initial time point, F(1,254)=76.244, p < 0.001. The significant interaction of statins is achieved with aspirin F(1,252)= 3.921, p=0.049, while interactions with other medicaments are insignificant for CAD Score. The results showed that there was no significant interaction of statins and dyslipidemia, F(1,251)=0.877, p = 0.350. Also, there was no significant interaction of statins and hypertension, F(1,245)=0.283, p=0.596. The CAD score in the baseline was significantly different among patients who were further prescribed with therapy than those who were not, and this trend remained unchanged after a given time period, i.e. those patients who were at risk had progression in addition to statins, but the combination of statins and aspirin was shown as effective in decreasing the CAD Score. The Random Forest classifier applied on 24 selected features is the most reliable among all tested ML algorithms for the prediction of CAD progress.

Statins and Inflammation in Cardiovascular Disease

2018 ◽  
Vol 23 (46) ◽  
pp. 7027-7039 ◽  
Author(s):  
Georgia Vogiatzi ◽  
Evangelos Oikonomou ◽  
Gerasimos Siasos ◽  
Sotiris Tsalamandris ◽  
Alexandros Briasoulis ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Lipid Lowering ◽  
Hmg Coa Reductase ◽  
Ample Evidence ◽  
Reductase Inhibitors ◽  
Immune System Activation ◽  
Hmg Coa Reductase Inhibitors ◽  
Anti Inflammatory ◽  
Artery Disease ◽  
Coa Reductase

Background: Chronic inflammation and immune system activation underlie a variety of seemingly unrelated cardiac conditions including not only atherosclerosis and the subsequent coronary artery disease but also peripheral artery disease, hypertension with target organ damage and heart failure. The beneficial effects of HMG-CoA reductase inhibitors or statins are mainly attributed to their ability to inhibit hepatic cholesterol biosynthesis. Beyond their lipid lowering activity, ample evidence exists in support of their potent anti-inflammatory properties which initiate from the inhibition of GTPase isoprenylation, activating a cataract of secondary pathways and extend to the inhibition and blocking of immune cell activation and interaction. </P><P> Objective: To summarize the anti-inflammatory mechanisms of statins in clinical and experimental settings in cardiovascular disease. </P><P> Methods: A systematic search of PubMed and the Cochrane Database was conducted in order to identify the majority of trials, studies, current guidelines and novel articles related to the subject. </P><P> Results: In vitro, statins have immuno-modulatory and anti-inflammatory effects, and they can exert antiatherosclerotic effects independently of their hypolipidemic actions. In addition, positive results have emerged from mechanistic and experimental studies on the active role of HMG-CoA reductase inhibitors in HF. By extrapolating those data in clinical setting, we further understand how HMG-CoA reductase inhibitors can beneficially affect not only systolic but also diastolic HF. </P><P> Conclusion: In this review article, we present the basic pathophysiologic data supporting the anti-inflammatory actions of statins in clinical and experimental settings and we link these mechanisms with confirmatory clinical data on the potent non lipid lowering effects of HMG-CoA reductase inhibitors.

Sign in / Sign up

Export Citation Format

Share Document